Prenuvo Announces it Had Raised $120M to Advance Preventative Health, Launches Novel FDA-Cleared AI-Powered Products

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Prenuvo, the leader in proactive whole-body MRI screening, today disclosed that it quietly raised $120M as part of Series B fundraising during 2024, demonstrating its category leadership in preventative health. The company has identified over 1.4 million personalized health insights across its member base, highlighting the critical role of early detection. This milestone comes as Prenuvo surpassed 110,000 members and secured FDA clearance for its AI-powered Prenuvo Body Composition report.

“Prenuvo is leading a movement to make proactive healthcare accessible and transformative for everyone,” said Andrew Lacy, CEO of Prenuvo Inc. “We’re introducing a new approach to early detection that empowers individuals to take control of their health before symptoms emerge. This isn’t just about healthcare; it’s about reimagining how we approach health, using cutting-edge technology and world-class expertise to prevent disease and help people live longer, healthier lives.”

The round, co-led by Forerunner Ventures, Left Lane Capital, and existing investor Felicis, has accelerated Prenuvo’s augmentation of its core industry-leading whole-body MRI screening with additional modalities and analyses of the human body.

Innovative Product Expansion

Prenuvo today announced FDA clearance for its AI-powered Prenuvo Body Composition report, marking a significant milestone in the company’s growth. Building on this momentum, Prenuvo introduces three major advances:

• FDA-cleared, AI-powered whole-body composition analysis platform that is non-invasive and delivers precise, actionable, and quantitative data on visceral fat, subcutaneous fat, liver fat, muscle volumes, as well as the volume of vital abdominal organs – providing patients with a personalized report to make informed lifestyle choices and proactive health decisions.
• Groundbreaking new brain health scan that equips patients with critical data on brain function, cognitive health, and early indicators of neurodegenerative conditions.
• Comprehensive functional and conventional blood bio-marker assessment that uses a custom built panel of blood tests to provide insights into metabolic, cardiovascular, hormonal, and immune health. Designed to work symbiotically with imaging to deepen health insights.

These new capabilities will launch immediately in a bundled offering called Prenuvo Enhanced in Silicon Valley, Los Angeles and New York locations, with other locations offering these enhanced screenings in the spring. To sign up for a waitlisted location, visit https://natural-energy.news/enhanced-screening%3C/a%3E%3C/p%3E%3Cp%3E%E2%80%9CLast year demonstrated an unmistakable shift in consumer behavior towards proactive health management,” said Sundeep Peechu, Managing Partner at Felicis. “Prenuvo has a unique integrated model that is difficult to replicate, and their advanced screening positions them to lead this transformation in preventative healthcare.”

Deliberate Growth and Clinical Excellence

Prenuvo has built the world’s largest private radiology group focused solely on whole-body MRI, with over 80 board-certified radiologists. This expertise has driven research collaborations with premier academic centers studying health, aging, and disease through the unique combination of MRI and AI.

Unlike others who outsource both imaging and radiology services, Prenuvo is fully vertically integrated, owning and operating 17 dedicated centers across North America. With a growing movement to prioritize preventative healthcare, Prenuvo will bring its revolutionary approach to 15 more clinics, including Europe and Australia, marking its first international expansion outside of North America.

“With only 2.5% of healthcare spending focused on preventative medicine, the US system waits for people to become sick before intervening,” said Brian O’Malley from Forerunner. “Consumers have grown tired of this and are responding with their own wallets. Prenuvo is the preeminent solution for a comprehensive understanding of one’s health, giving today’s patients unprecedented levels of knowledge to not just understand, but proactively intervene in the challenges that arise as we all age. Longevity is the new luxury and Prenuvo is democratizing access so that more can benefit from this.”

“Prenuvo has empowered patients in ways that conventional medical care simply hasn’t. Consumers are taking ownership and seeking answers outside of the traditional healthcare system. The physician and clinical ecosystem is waking up to the needs and wants of their patients, who are increasingly demanding proactive and preventative healthcare solutions like Prenuvo,” says Harley Miller, Managing Partner & CEO, Left Lane Capital. “We look forward to seeing how the team continues to scale, advance their proprietary research, and build on their life-changing (and saving) technology.”

About Prenuvo

Prenuvo makes MRI scanning for early detection of many types of cancer, “silent killers” like aneurysms, and other diseases seamless and more widely accessible. Combining cutting-edge analysis technology with radiation-free and non-invasive full-body scans, Prenuvo’s patient-centric design is optimized to assess the body holistically and in under 60 minutes, compared with the several hours it would take to achieve this level of insight from conventional MRI scans. Prenuvo, Inc. is the administrative and managerial services company for the affiliated Prenuvo physician-owned professional corporations that deliver medical services in-office and virtually. Prenuvo Inc. and the Prenuvo medical entities do business under the “Prenuvo” brand.

Prenuvo is backed by leading venture capital firms and investors in health, fitness and category-defining consumer brands such as Felicis [investors in Fitbit (IPO), Guardant Health (IPO) and Ring (acq. by Amazon)], 23AndMe CEO Anne Wojcicki, Nest founder Tony Fadell, Eric Schmidt, Cindy Crawford and Lasker award recipient Dr. Timothy A. Springer.

About Forerunner

Forerunner is a venture capital firm investing at the intersection of shifting consumer behavior and emerging, transformative technology. Founded in 2012, Forerunner has raised nearly $3 billion in assets under management, and is an early investor in, Chime, Faire, OURA, Hims & Hers, The Farmer’s Dog, Ritual, Headway, Prenuvo, Fora, Glossier, and more.

About Left Lane Capital

Founded in 2019, Left Lane Capital is a New York and London-based global venture capital and growth equity firm investing in hyper-growth consumer and SMB businesses with enduring customer relationships. Left Lane's mission is to partner with extraordinary entrepreneurs who create category-defining companies across growth sectors of the economy. Select investments include Talkiatry, Evvy, Pearl, Wayflyer, M1 Finance, Bilt Rewards, Blank Street, Kings League, Olipop, and more.

For more information, visit leftlane.com.

About Felicis

Founded in 2006, Felicis is a venture capital firm investing in companies reinventing core markets, as well as those creating frontier technologies. Felicis focuses on early-stage investments and currently manages over $3B in capital across 9 funds. The firm is an early backer of more than 50 companies valued at $1B+. More than 100 of its portfolio companies have been acquired or gone public, including Adyen (IPO), Credit Karma (acq by Intuit), Cruise (acq by General Motors), Fitbit (IPO), Guardant Health (IPO), Meraki (acq by Cisco), Ring (acq by Amazon), and Shopify (IPO). The firm is based in Menlo Park and San Francisco in California. Learn more at felicis.com.

Contacts

Media Contact:
Christine Alabastro
media@prenuvo.com